What is APP13007, 0.1% used for?

APP13007, 0.1% is indicated for Type 2 diabetes.

Who makes APP13007, 0.1%?

APP13007, 0.1% is developed by Formosa Pharmaceuticals, Inc..

What are the side effects of APP13007, 0.1%?

Common side effects include Nausea, Diarrhea, Vomiting.

Last reviewed 2026-04-23 · How we verify

APP13007, 0.1%

Formosa Pharmaceuticals, Inc. · Phase 2 active Small molecule

APP13007 is a small molecule that targets the SGLT2 receptor.

APP13007 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Generic name	APP13007, 0.1%
Sponsor	Formosa Pharmaceuticals, Inc.
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 2

Mechanism of action

By inhibiting SGLT2, APP13007 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.

Approved indications

Type 2 diabetes

Common side effects

Nausea
Diarrhea
Vomiting

Key clinical trials

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

APP13007, 0.1% CI brief — competitive landscape report
APP13007, 0.1% updates RSS · CI watch RSS
Formosa Pharmaceuticals, Inc. portfolio CI